Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas [electronic resource] /
edited by Andrés J. M. Ferreri.
- 1st ed. 2018.
- XIII, 138 p. 14 illus., 13 illus. in color. online resource.
- Resistance to Targeted Anti-Cancer Therapeutics, 17 2196-5501 ; .
- Resistance to Targeted Anti-Cancer Therapeutics, 17 .
Acceso multiusuario
Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .
9783319751849
Cancer research.
Molecular biology.
Cancer Research.
Molecular Medicine.
RC261-271
614.5999
Acceso multiusuario
Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .
9783319751849
Cancer research.
Molecular biology.
Cancer Research.
Molecular Medicine.
RC261-271
614.5999
